Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 25, 2017

View Archived Issues

Merus closes bispecific antibody research collaboration with Incyte

EMA grants accelerated assessment to glecaprevir/pibrentasvir MAA

Ocular Therapeutix resubmits NDA for Dextenza

TG Therapeutics obtains another FDA orphan drug designation for TG-1101/TGR-1201 combination

CECR1 as a novel drug target for selective modulation of the M2-like TAMs in glioma

Evestra Onkologia awarded grant to support endometriosis drug development

Phase III study of OSE Immunotherapeutics' Tedopi cleared to continue

Intrexon to acquire GenVec

SUBQ-HF study of scPharmaceuticals' subcutaneous furosemide begins

Asterias reports encouraging data from ongoing phase I/IIa study of AST-OPC1 in spinal cord injury

Medicines Patent Pool and Johns Hopkins sign license agreement for sutezolid to treat TB

Agios Pharmaceuticals reviews pipeline in recent presentation

Neovacs advisory board recommends development of IFN-alpha kinoid for type 1 diabetes

Rodin Therapeutics discovers new HDAC2 inhibitors

Aptuit and Massachusetts General Hospital enter drug discovery collaboration

Sage Therapeutics patents novel NMDA receptor modulators

Intra-Cellular Therapies gives update on lumateperone and other programs

Phase III trial of Lenvima in first-line unresectable HCC meets primary endpoint

Mitsubishi Tanabe Pharma discovers MMP-9 production inhibitors

GlaxoSmithKline synthesizes novel BMP-1, TLL1 and TLL2 inhibitors

Rice University presents novel shishijimicin A analogues

NIH grant supports development at Scripps Research Institute of ASK-1 inhibitors

Grant supports Discuva's work to develop novel antibiotics to tackle multidrug-resistance

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...